drugset
drugset / Trial / NCT05164614

Study Evaluating PK of PTH Administered Orally Via RaniPill™ Capsule

NCT05164614 ↗

Phase 1 Completed 50 enrolled RANI Therapeutics
Non-randomizedParallel-groupOpen-labelTreatment

Summary

A prospective, single-center, open-label, phase I study evaluating the pharmacokinetics (PK) of human parathyroid hormone (1-34) ("PTH") administered via the RaniPill™ capsule ("RT-102").

Timeline

Start
2022-02-21
Primary completion
2022-10-10
Completion
2022-10-17

Drugs

EvaluationDrugModalityDoseRoute
Subject Parathyroid Hormone (1-34) Peptide 20 ug Oral
Subject Parathyroid Hormone (1-34) Peptide 80 ug Oral
Comparator Teriparatide Protein / enzyme biologic 20 ug Subcutaneous

Indications

No indication recorded.